A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (D…

Overview of attention for article published in European Journal of Heart Failure, March 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 6 news stories from 5 outlets.

Sans hésitation possible, l’insuffisance cardiaque (IC) est une des principales préoccupations en santé publique en France.

There are several new tools being added to the clinical armamentarium in the fight against heart failure (HF).

October 21, 2019 – The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farx…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.